載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.611
−US$0.034 · -5.27%
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
一般交易時段
US$0.611
−US$0.034 · -5.27%
盤中時間採用ET。市場資料可能有所延遲。
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
日內區間
目前US$0.611
52週區間
目前US$0.611
盤中時間採用ET。市場資料可能有所延遲。
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
日內區間
目前US$0.611
52週區間
目前US$0.611
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$9.50
上漲空間 1454.83%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI139.61萬0.00%2.3兆 USD0.03%US$380.27-0.20%
Vanguard Extended Market ETFVXF54.2萬0.00%954億 USD0.05%US$232.56-0.40%
iShares Russell 2000 ETFIWM32.24萬0.00%785.63億 USD0.19%US$276.32-0.50%
Vanguard Russell 2000 ETFVTWO23.44萬0.00%180億 USD0.06%US$111.59-0.55%
Fidelity Enhanced Small Cap ETFFESM11.8萬—64.1億 USD0.28%US$44.965-0.56%
iShares Micro-Cap ETFIWC4.09萬0.00%13.33億 USD0.60%US$181.9-0.80%
Invesco NASDAQ Future Gen 200 ETFQQQS3.76萬0.16%2296.09萬 USD0.20%US$41.3983-1.49%
Vanguard Russell 2000 Value ETFVTWV3.24萬0.00%14億 USD0.06%US$184.6-0.20%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMiShares Micro-Cap ETFIWCInvesco NASDAQ Future Gen 200 ETFQQQSVanguard Russell 2000 Value ETFVTWVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
